TLSI
TriSalus Life·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
TLSI Profile
Trisalus Life Sciences, Inc.
An immunotherapy company that develops and commercialises therapies using a three-pronged therapeutic approach combining immunomodulation therapy, tumour-killing agents, and a proprietary intravascular regional delivery technology for the treatment of liver and pancreatic tumours
Life Science Tools and Services
--
02/08/2021
NASDAQ Stock Exchange
110
12-31
Common stock
6272 W. 91st Ave.
, Westminster, Colorado 80031
--
TriSalus Life Sciences, Inc., a Delaware corporation, was founded in 2009. They are engaged in the research, development and sales of innovative drug delivery technologies and immuno-oncology therapies to improve the treatment of hard-to-treat liver and pancreatic cancers. Their techniques are used to provide treatment and are administered by interventional radiologists. They are developing and marketing two product lines — the Pressure Drug Delivery System (PEDD), which is currently in use, and an investigational drug, SD-101, which has shown potential to enhance the immune system response in the treatment of hepatocellular carcinoma, pancreatic cancer and other solid tumors of the liver. Their PEDD with SmartValve is the only technology that works in sync with the cardiac cycle, opening collapsed blood vessels within the tumor to achieve deeper perfusion and improve delivery of therapeutic drugs in the case of high pressure within the tumor. PEDD and SmartValve have been shown to improve treatment uptake and tumor response in prospective and retrospective clinical studies and multiple preclinical models.
